argenx SE (ARGNF)
OTCMKTS
· Delayed Price · Currency is USD
569.19
0.00 (0.00%)
At close: Jun 24, 2025
argenx SE Revenue
argenx SE had revenue of $807.37M in the quarter ending March 31, 2025, with 95.72% growth. This brings the company's revenue in the last twelve months to $2.64B, up 82.13% year-over-year. In the year 2024, argenx SE had annual revenue of $2.25B with 77.22% growth.
Revenue (ttm)
2.64B
Revenue Growth
+82.13%
P/S Ratio
12.58
Revenue / Employee
1.65M
Employees
1,599
Market Cap
33.25B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 2.25B | 979.61M | 77.22% |
| Dec 31, 2023 | 1.27B | 827.58M | 187.66% |
| Dec 31, 2022 | 441.01M | -87.25M | -16.52% |
| Dec 31, 2021 | 528.27M | 466.31M | 752.59% |
| Dec 31, 2020 | 61.96M | -30.85M | -33.24% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Endo, Inc. | 1.73B |
| Elite Pharmaceuticals | 70.00M |
| Veradigm | 588.02M |
| Tian'an Technology Group | 1.78M |
| American Oncology Network | 1.76B |
| Glass House Brands | 215.62M |
| Northwest Biotherapeutics | 1.47M |
| Silence Therapeutics | 27.70M |
argenx SE News
- 7 days ago - argenx gets EU nod for Vyvgart subcutaneous injection - Seeking Alpha
- 7 days ago - argenx Announces European Commission Approval of VYVGART Subcutaneous Injection for Chronic Inflammatory Demyelinating Polyneuropathy - GlobeNewsWire
- 11 days ago - $1000 Invested In This Stock 5 Years Ago Would Be Worth This Much Today - Benzinga
- 17 days ago - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease - Benzinga
- 17 days ago - argenx Presents New Efgartigimod Data at EULAR 2025 Highlighting Positive Phase 2 Proof-of-Concept Results in Myositis and Sjogren's Disease - GlobeNewsWire
- 25 days ago - argenx to Present at Goldman Sachs 46th Annual Global Healthcare Conference - GlobeNewsWire
- 4 weeks ago - argenx Announces Results of Annual General Meeting of Shareholders - GlobeNewsWire
- 5 weeks ago - Hot Picks in biotech: argenx, Scholar Rock & Kiniksa - BNN Bloomberg